Skip to main content
Fig. 7 | Cost Effectiveness and Resource Allocation

Fig. 7

From: Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States

Fig. 7

The acceptability curve of the Markov model in China (A) and in the United States (B). CE, cost effectiveness. X-axis: Willingness-to-pay (WTP) threshold (measured in RMB/QALY for China and USD/QALY for the United States). Y-axis: Probability that the treatment is cost-effective (ranging from 0 to 100%). Curves: Each curve represents the probability that a specific treatment (e.g., Olaparib) is cost-effective at different WTP thresholds

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us